Literature DB >> 26410019

"Score the Core" Web-based pathologist training tool improves the accuracy of breast cancer IHC4 scoring.

Jesse A Engelberg1, Hanna Retallack2, Ronald Balassanian3, Mitchell Dowsett4, Lila Zabaglo5, Arishneel A Ram6, Sophia K Apple7, John W Bishop8, Alexander D Borowsky8, Philip M Carpenter9, Yunn-Yi Chen3, Brian Datnow10, Sarah Elson6, Farnaz Hasteh10, Fritz Lin9, Neda A Moatamed7, Yanhong Zhang8, Robert D Cardiff8.   

Abstract

Hormone receptor status is an integral component of decision-making in breast cancer management. IHC4 score is an algorithm that combines hormone receptor, HER2, and Ki-67 status to provide a semiquantitative prognostic score for breast cancer. High accuracy and low interobserver variance are important to ensure the score is accurately calculated; however, few previous efforts have been made to measure or decrease interobserver variance. We developed a Web-based training tool, called "Score the Core" (STC) using tissue microarrays to train pathologists to visually score estrogen receptor (using the 300-point H score), progesterone receptor (percent positive), and Ki-67 (percent positive). STC used a reference score calculated from a reproducible manual counting method. Pathologists in the Athena Breast Health Network and pathology residents at associated institutions completed the exercise. By using STC, pathologists improved their estrogen receptor H score and progesterone receptor and Ki-67 proportion assessment and demonstrated a good correlation between pathologist and reference scores. In addition, we collected information about pathologist performance that allowed us to compare individual pathologists and measures of agreement. Pathologists' assessment of the proportion of positive cells was closer to the reference than their assessment of the relative intensity of positive cells. Careful training and assessment should be used to ensure the accuracy of breast biomarkers. This is particularly important as breast cancer diagnostics become increasingly quantitative and reproducible. Our training tool is a novel approach for pathologist training that can serve as an important component of ongoing quality assessment and can improve the accuracy of breast cancer prognostic biomarkers.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Digital microscopy; IHC4; Immunohistochemistry; Pathology education; Training; Whole-slide imaging

Mesh:

Substances:

Year:  2015        PMID: 26410019     DOI: 10.1016/j.humpath.2015.07.008

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

1.  Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement.

Authors:  Jeannine S McCune; Christine M Quinones; James Ritchie; Paul A Carpenter; Erik van Maarseveen; Rosa F Yeh; Claudio Anasetti; Jaap J Boelens; Nelson Hamerschlak; Moustapha Hassan; Hyoung Jin Kang; Yoshinobu Kanda; Angelo Paci; Miguel-Angel Perales; Peter J Shaw; Victoria L Seewaldt; Bipin N Savani; Angela Hsieh; Betsy Poon; Mohamad Mohty; Michael A Pulsipher; Marcelo Pasquini; L Lee Dupuis
Journal:  Biol Blood Marrow Transplant       Date:  2019-05-25       Impact factor: 5.742

Review 2.  Emerging Themes in Image Informatics and Molecular Analysis for Digital Pathology.

Authors:  Rohit Bhargava; Anant Madabhushi
Journal:  Annu Rev Biomed Eng       Date:  2016-07-11       Impact factor: 9.590

Review 3.  Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists.

Authors:  Nicola Fusco; Moira Ragazzi; Elham Sajjadi; Konstantinos Venetis; Roberto Piciotti; Stefania Morganti; Giacomo Santandrea; Giuseppe Nicolò Fanelli; Luca Despini; Marco Invernizzi; Bruna Cerbelli; Cristian Scatena; Carmen Criscitiello
Journal:  Histol Histopathol       Date:  2021-09-29       Impact factor: 2.303

4.  Elevated Foxp3/CD8 Ratio in Lung Adenocarcinoma Metastatic Lymph Nodes Resected by Transcervical Extended Mediastinal Lymphadenectomy.

Authors:  Joanna Domagala-Kulawik; Iwona Kwiecien; Juliusz Pankowski; Monika Pasieka-Lis; Dominika Wolosz; Marcin Zielinski
Journal:  Biomed Res Int       Date:  2017-08-02       Impact factor: 3.411

5.  Comparison of Multiplexed Immunofluorescence Imaging to Chromogenic Immunohistochemistry of Skin Biomarkers in Response to Monkeypox Virus Infection.

Authors:  Anup Sood; Yunxia Sui; Elizabeth McDonough; Alberto Santamaría-Pang; Yousef Al-Kofahi; Zhengyu Pang; Peter B Jahrling; Jens H Kuhn; Fiona Ginty
Journal:  Viruses       Date:  2020-07-23       Impact factor: 5.048

6.  Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.

Authors:  Linda S Lindström; Christina Yau; Kamila Czene; Carlie K Thompson; Katherine A Hoadley; Laura J Van't Veer; Ron Balassanian; John W Bishop; Philip M Carpenter; Yunn-Yi Chen; Brian Datnow; Farnaz Hasteh; Gregor Krings; Fritz Lin; Yanhong Zhang; Bo Nordenskjöld; Olle Stål; Christopher C Benz; Tommy Fornander; Alexander D Borowsky; Laura J Esserman
Journal:  J Natl Cancer Inst       Date:  2018-07-01       Impact factor: 13.506

7.  Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.

Authors:  Annelie Johansson; Nancy Y Yu; Adina Iftimi; Nicholas P Tobin; Laura van 't Veer; Bo Nordenskjöld; Christopher C Benz; Tommy Fornander; Gizeh Perez-Tenorio; Olle Stål; Laura J Esserman; Christina Yau; Linda S Lindström
Journal:  Int J Cancer       Date:  2022-03-07       Impact factor: 7.316

8.  Prognostic Value of GPNMB, EGFR, p-PI3K, and Ki-67 in Patients with Esophageal Squamous Cell Carcinoma.

Authors:  Bo Wang; Mengyan Li; Anna Su; Yongmei Gao; Yan Shi; Chao Li; Wenying Liu; Liping Su; Wan Li; Yuqing Ma
Journal:  Anal Cell Pathol (Amst)       Date:  2022-08-31       Impact factor: 4.133

9.  Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.

Authors:  Huma Dar; Annelie Johansson; Anna Nordenskjöld; Adina Iftimi; Christina Yau; Gizeh Perez-Tenorio; Christopher Benz; Bo Nordenskjöld; Olle Stål; Laura J Esserman; Tommy Fornander; Linda S Lindström
Journal:  JAMA Netw Open       Date:  2021-06-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.